A new face in the treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19845 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Takeshi Kondo. Beteiligte Einrichtung: Blood Disorders Center, Aiiku Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Philadelphia Chromosome. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
The prognosis for patients with relapsed/refractory or measurable (minimal) residual disease‐positive Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukaemia (ALL) is poor. Currently, ponatinib is the only approved tyrosine kinase inhibitor (TKI) that is effective for Ph‐positive ALL with the T315I mutation. Although the report by Liu et al. is a retrospective observational study, it offers prospects for the efficacy of chemotherapy combined with the novel third‐generation TKI, olverembatinib, in these conditions, which may be validated in future prospective clinical trials. Commentary on: Liu et al. Efficacy and safety of olverembatinib in adult BCR::ABL1‐positive ALL with T315I mutation or relapsed/refractory disease. Br J Haematol 2024; 205: 2228‐2233 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
ORCID-Profile: Takeshi Kondo
Zitieren
APA
Kondo, T. (2024). A new face in the treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19845
Vancouver
Kondo T. A new face in the treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia. British Journal of Haematology. 2024. doi:10.1111/bjh.19845
BibTeX
@article{Kondo2024,
author = {Kondo, Takeshi},
title = {A new face in the treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19845}
}
EUVIMED